Shares of Applied Therapeutics (NASDAQ:APLT) have received an average broker rating score of 1.00 (Strong Buy) from the three analysts that provide coverage for the company, Zacks Investment Research reports. Three analysts have rated the stock with a strong buy recommendation.
Brokers have set a 12-month consensus target price of $26.50 for the company and are forecasting that the company will post ($0.39) earnings per share for the current quarter, according to Zacks. Zacks has also assigned Applied Therapeutics an industry rank of 77 out of 256 based on the ratings given to related companies.
Several analysts have commented on the company. UBS Group assumed coverage on Applied Therapeutics in a report on Monday. They issued a “buy” rating on the stock. Cowen assumed coverage on Applied Therapeutics in a report on Monday. They issued an “outperform” rating on the stock. Robert W. Baird assumed coverage on Applied Therapeutics in a report on Monday. They issued an “outperform” rating and a $24.00 price objective on the stock. Finally, Citigroup assumed coverage on Applied Therapeutics in a report on Monday. They issued a “buy” rating and a $29.00 price objective on the stock.
APLT traded up $0.08 during trading on Wednesday, hitting $10.00. The company’s stock had a trading volume of 32,365 shares, compared to its average volume of 67,116. Applied Therapeutics has a twelve month low of $7.95 and a twelve month high of $11.20.
Applied Therapeutics Company Profile
Applied Therapeutics, Inc, a biopharmaceutical company, develops novel products to target cardiovascular disease, galactosemia, and diabetic complications. Its lead product candidate is AT-001 that is in phase II clinical trials for treating diabetic cardiomyopathy, as well as is in phase I clinical trials to treat diabetic peripheral neuropathy.
Featured Story: What is a conference call?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Applied Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Applied Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.